LUNG - NASDAQ

Pulmonx Corporation

LUNG·NASDAQ

$1.60

+1.9%

HealthcareMedical - Devices

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$67.79M

EPS-1.3300

P/E Ratio-1.21

Earnings Date07/29/2026

129.29M

Assets

-21%

3Y-33.0%

5Y-51.0%

10Y+761.0%

75.17M

Total Liabilities

-2%

3Y+90.0%

5Y+100.0%

10Y-59.0%

54.12M

Total Equity

-37%

3Y-65.0%

5Y-76.0%

10Y-132.0%

Pulmonx Corporation Funding & Solvency Profile

LUNG · NASDAQ

Current Assets

Cash & Cash Equivalents70.01M

Net Receivables12.07M

Inventory15.85M

Other Current Assets3.76M

Total Current Assets102 M

Non-Current Assets

Property, Plant & Equipment20.25M

Goodwill & Intangible Assets2.33M

Long-Term Investments0.00

Other Non-Current Assets5.03M

Total Non-Current Assets25 M

Total Assets

129.29M

Financial Health Analysis

Current Ratio

5.07x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.39x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

82 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

79% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Pulmonx Corporation Balance Sheet

LUNG • NASDAQ

Pulmonx Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	70M	70.9M	83.5M	101.7M	148.5M	231.8M	14.8M	4.1M
Short-Term Investments	0.0	30.6M	33.6M	39.4M	31.6M	0.0	13.6M	0.0
Cash & Short-Term Investments	70M	101.5M	117.1M	141.1M	180M	231.8M	28.3M	4.1M
Net Receivables	12.1M	13.8M	13M	9.3M	6.9M	4.6M	6M	3.4M
Accounts Receivables	12.1M	13.1M	12.1M	8.7M	6.6M	4.2M	5.5M	3M
Other Receivables	0.0	671K	915K	602K	362K	339K	487K	471K
Inventory	15.8M	16.9M	16.7M	14.6M	16.3M	10.7M	5.6M	3.3M
Prepaids	0.0	2.7M	2.8M	3.5M	4.2M	2.5M	448K	318K
Other Current Assets	3.8M	1.4M	741K	521K	578K	377K	666K	125K
Total Current Assets	101.7M	136.2M	150.4M	169M	208M	250M	41.1M	11.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	20.2M	21.5M	7.4M	10.5M	12.9M	10.5M	7.5M	375K
Goodwill	2.3M	2.3M	2.3M	2.3M	2.3M	2.3M	2.3M	2.3M
Intangible Assets	0.0	0.0	31K	154K	277K	400K	524K	647K
Goodwill & Intangible Assets	2.3M	2.3M	2.4M	2.5M	2.6M	2.7M	2.9M	3M
Long-Term Investments	0.0	0.0	14.4M	5.9M	10.9M	0.0	0.0	0.0
Other Non-Current Assets	5M	2.8M	3.2M	5.8M	731K	536K	2.1M	350K
Total Non-Current Assets	27.6M	26.6M	27.4M	24.7M	27.2M	13.7M	12.5M	3.7M
Total Assets	129.3M	162.9M	177.8M	193.7M	235.2M	263.7M	53.5M	15M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.2M	4.7M	2.4M	2.4M	2.5M	1.6M	2.9M	2M
Accounts Payable	3.9M	3.8M	1.5M	1.8M	1.6M	1.5M	2.7M	1.3M
Other Payables	263K	876K	856K	646K	877K	94K	233K	730K
Accrued Expenses	0.0	8.8M	7.6M	7.7M	7.9M	5.6M	4.2M	3.4M
Short Term Debt	1.3M	3.2M	2.2M	90K	91K	2.2M	0.0	0.0
Capital Lease Obligations (Current)	0.0	778K	3.1M	3.2M	2.2M	0.0	446K	0.0
Tax Payables	0.0	876K	93K	646K	877K	94K	995K	730K
Deferred Revenue	18K	135K	104K	120K	163K	71K	173K	139K
Other Current Liabilities	14.6M	6.9M	7.9M	5M	4.7M	3.1M	6.5M	2.5M
Total Current Liabilities	20.1M	24.4M	23.2M	18.5M	17.6M	12.5M	14.2M	8.1M
NON-CURRENT LIABILITIES
Long Term Debt	37M	34M	35.1M	17.2M	17.3M	17.4M	220.3M	33.6M
Deferred Tax Liabilities (Non-Current)	69K	87K	114K	94K	37K	62K	43K	48K
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	179K	0.0	0.0	140.6M
Total Non-Current Liabilities	55.1M	52.6M	36.3M	21.2M	24.4M	25M	226.8M	174.3M
Capital Lease Obligations	18.1M	19.3M	4.2M	7.1M	9M	7.6M	6.8M	0.0
Total Liabilities	75.2M	77M	59.5M	39.7M	41.9M	37.6M	240.9M	182.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	205.3M	140.5M
Common Stock	42K	40K	39K	38K	37K	36K	19K	17K
Additional Paid-In Capital	573.3M	551.2M	526.8M	502.7M	482.9M	467.1M	21.7M	21.1M
Retained Earnings	-521.6M	-467.6M	-411.2M	-350.3M	-291.4M	-242.7M	-210.5M	-189.8M
Accumulated Other Comprehensive Income/Loss	2.4M	2.1M	2.6M	1.6M	1.7M	1.7M	1.4M	1.3M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	17K	0.0
Total Stockholders' Equity	54.1M	85.8M	118.3M	154M	193.2M	226.1M	-187.4M	-167.3M
Total Equity	54.1M	85.8M	118.3M	154M	193.2M	226.1M	-187.4M	-167.3M
SUMMARY
Total Liabilities & Equity	129.3M	162.9M	177.8M	193.7M	235.2M	263.7M	53.5M	15M
Total Investments	0.0	30.6M	47.9M	45.3M	42.5M	0.0	13.6M	0.0
Total Debt	56.4M	56.5M	41.4M	24.4M	26.5M	27.2M	21.8M	33.6M
Net Debt	-13.6M	-14.4M	-42.1M	-77.3M	-122M	-204.6M	7M	29.5M
Shares Outstanding	40,746,556	40,746,556	40,746,556	40,746,556	40,746,556	40,746,556	40,746,556	40,746,556

SEC Filings

LUNG - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	June 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	November 24, 2025	November 24, 2025		View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 27, 2025	October 21, 2025	2025	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your LUNG research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.